{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=placebo+for+fenofibrate",
    "query": {
      "intervention": "placebo for fenofibrate"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 32,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=placebo+for+fenofibrate&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-24T22:21:55.898Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00400231",
      "title": "The Fenofibrate and Metformin for Atherogenic Dyslipidemia (FAMA) Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metabolic Syndrome x"
      ],
      "interventions": [
        {
          "name": "Study drugs: Metformin and fenofibrate",
          "type": "DRUG"
        },
        {
          "name": "Study Drug: Metformin",
          "type": "DRUG"
        },
        {
          "name": "Study Drug: fenofibrate",
          "type": "DRUG"
        },
        {
          "name": "Metformin and Fenofibrate placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 124,
      "start_date": "2005-08",
      "completion_date": "2008-03",
      "has_results": false,
      "last_update_posted_date": "2017-03-20",
      "last_synced_at": "2026-09-24T22:21:55.898Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00400231"
    },
    {
      "nct_id": "NCT01574131",
      "title": "Acute and Long-Term Outcome Investigations of Fenofibrate on Severely Burned Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Second or Third Degree Burns"
      ],
      "interventions": [
        {
          "name": "Fenofibrate",
          "type": "DRUG"
        },
        {
          "name": "Sugar Pill",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The University of Texas Medical Branch, Galveston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "20 Years",
        "sex": "ALL",
        "summary": "4 Years to 20 Years"
      },
      "enrollment_count": 3,
      "start_date": "2012-05",
      "completion_date": "2016-02",
      "has_results": false,
      "last_update_posted_date": "2019-11-29",
      "last_synced_at": "2026-09-24T22:21:55.898Z",
      "location_count": 1,
      "location_summary": "Galveston, Texas",
      "locations": [
        {
          "city": "Galveston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01574131"
    },
    {
      "nct_id": "NCT00559962",
      "title": "Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hyperlipidemia"
      ],
      "interventions": [
        {
          "name": "AEGR-733",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        },
        {
          "name": "AEGR-733 and atorvastatin",
          "type": "DRUG"
        },
        {
          "name": "AEGR-733 and fenofibrate",
          "type": "DRUG"
        },
        {
          "name": "AEGR-733 and ezetimibe",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aegerion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 260,
      "start_date": "2007-10",
      "completion_date": "2008-11",
      "has_results": true,
      "last_update_posted_date": "2018-02-23",
      "last_synced_at": "2026-09-24T22:21:55.898Z",
      "location_count": 15,
      "location_summary": "San Diego, California • Santa Rosa, California • Washington D.C., District of Columbia + 10 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Santa Rosa",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00559962"
    },
    {
      "nct_id": "NCT00542178",
      "title": "Evaluating How the Treatments in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Affect Diabetic Retinopathy (The ACCORD Eye Study)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetic Retinopathy"
      ],
      "interventions": [
        {
          "name": "Hypoglycemic Agents",
          "type": "DRUG"
        },
        {
          "name": "Standard glycemia control",
          "type": "DRUG"
        },
        {
          "name": "Intensive BP treatment",
          "type": "DRUG"
        },
        {
          "name": "Standard BP control",
          "type": "DRUG"
        },
        {
          "name": "Fenofibrate",
          "type": "DRUG"
        },
        {
          "name": "Simvastatin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "40 Years to 79 Years"
      },
      "enrollment_count": 3472,
      "start_date": "2003-10",
      "completion_date": "2009-12",
      "has_results": true,
      "last_update_posted_date": "2018-07-24",
      "last_synced_at": "2026-09-24T22:21:55.898Z",
      "location_count": 6,
      "location_summary": "Minneapolis, Minnesota • New York, New York • Winston-Salem, North Carolina + 3 more",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00542178"
    },
    {
      "nct_id": "NCT00252499",
      "title": "Insulin Resistance in Non-alcoholic Fatty Liver Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Fatty Liver",
        "Insulin Resistance"
      ],
      "interventions": [
        {
          "name": "rosiglitazone",
          "type": "DRUG"
        },
        {
          "name": "fenofibrate",
          "type": "DRUG"
        },
        {
          "name": "placebo for rosiglitazone",
          "type": "DRUG"
        },
        {
          "name": "placebo for fenofibrate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "US Department of Veterans Affairs",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 13,
      "start_date": "2005-10",
      "completion_date": "2010-08",
      "has_results": true,
      "last_update_posted_date": "2014-08-20",
      "last_synced_at": "2026-09-24T22:21:55.898Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00252499"
    },
    {
      "nct_id": "NCT01025492",
      "title": "Study of Trilipix Effects on Lipids and Arteries",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Dyslipidemia"
      ],
      "interventions": [
        {
          "name": "Trilipix",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "30 Years to 75 Years"
      },
      "enrollment_count": 24,
      "start_date": "2009-11",
      "completion_date": "2011-03",
      "has_results": true,
      "last_update_posted_date": "2016-09-01",
      "last_synced_at": "2026-09-24T22:21:55.898Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01025492"
    },
    {
      "nct_id": "NCT01048502",
      "title": "Fenofibrate and Omega-3 Fatty Acid Modulation of Endotoxemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cardiovascular Disease"
      ],
      "interventions": [
        {
          "name": "Fenofibrate (Tricor) tablets",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Lovaza",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 100,
      "start_date": "2010-01",
      "completion_date": "2011-05",
      "has_results": true,
      "last_update_posted_date": "2016-02-19",
      "last_synced_at": "2026-09-24T22:21:55.898Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01048502"
    },
    {
      "nct_id": "NCT00872599",
      "title": "The Effect of a Peroxisome Proliferator-activated Receptor (PPAR) Alpha Agonist on Cytochrome P450 (CYP) Monooxygenase Activity in Humans",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hypertension"
      ],
      "interventions": [
        {
          "name": "fenofibrate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 75,
      "start_date": "2009-09",
      "completion_date": "2012-01",
      "has_results": true,
      "last_update_posted_date": "2013-06-28",
      "last_synced_at": "2026-09-24T22:21:55.898Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00872599"
    },
    {
      "nct_id": "NCT00246376",
      "title": "Diet, Exercise, Niacin, and Fenofibrate to Reduce Heart Disease Risk Factors in Individuals With HIV Lipodystrophy or Dyslipidemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cardiovascular Diseases",
        "Heart Diseases",
        "HIV Infections",
        "Hyperlipidemia",
        "Hypertriglyceridemia",
        "Insulin Resistance",
        "Atherosclerosis"
      ],
      "interventions": [
        {
          "name": "Diet",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Exercise",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Niacin",
          "type": "DRUG"
        },
        {
          "name": "Fenofibrate",
          "type": "DRUG"
        },
        {
          "name": "Placebos",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 221,
      "start_date": "2004-01",
      "completion_date": "2012-02",
      "has_results": true,
      "last_update_posted_date": "2016-03-21",
      "last_synced_at": "2026-09-24T22:21:55.898Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00246376"
    },
    {
      "nct_id": "NCT01047683",
      "title": "Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hypertriglyceridemia"
      ],
      "interventions": [
        {
          "name": "AMR101 (ethyl icosapentate) - 4 g/day",
          "type": "DRUG"
        },
        {
          "name": "AMR101 (ethyl icosapentate) - 2 g/day",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amarin Pharma Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 229,
      "start_date": "2009-12",
      "completion_date": "2011-07",
      "has_results": true,
      "last_update_posted_date": "2022-04-25",
      "last_synced_at": "2026-09-24T22:21:55.898Z",
      "location_count": 18,
      "location_summary": "Sacramento, California • Golden, Colorado • Miami, Florida + 13 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Golden",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Ocala",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01047683"
    }
  ]
}